PMID- 36938650
OWN - NLM
STAT- MEDLINE
DCOM- 20230711
LR  - 20230711
IS  - 1346-8138 (Electronic)
IS  - 0385-2407 (Linking)
VI  - 50
IP  - 7
DP  - 2023 Jul
TI  - Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 
      Japanese cases.
PG  - 912-916
LID - 10.1111/1346-8138.16786 [doi]
AB  - Cutaneous angiosarcoma (CAS) is a rare and highly aggressive type of vascular 
      tumor. Although chemoradiotherapy with taxanes is recognized as a first-line 
      therapy for CAS, second-line therapy for CAS remains controversial. From the 
      above findings, the efficacy and safety profiles of taxane-switch (change 
      paclitaxel to docetaxel or vise), eribulin methylate, and pazopanib regimens in 
      second-line chemotherapy were evaluated retrospectively in 50 Japanese 
      taxane-resistant CAS patients. Although there was no significant difference in 
      progression-free survival (P = 0.3528) among the regimens, the incidence of all 
      adverse events (AEs) (P = 0.0386), as well as severe G3 or more AEs (P = 0.0477) 
      was significantly higher in the eribulin methylate group and pazopanib group than 
      in the taxane-switch group. The present data suggest that switching to another 
      taxane should be considered for the treatment of taxane-resistant CAS in 
      second-line therapy based on the safety profiles.
CI  - (c) 2023 Japanese Dermatological Association.
FAU - Fujimura, Taku
AU  - Fujimura T
AUID- ORCID: 0000-0001-6809-5833
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Maekawa, Takeo
AU  - Maekawa T
AUID- ORCID: 0000-0001-5865-8487
AD  - Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
FAU - Kato, Hiroshi
AU  - Kato H
AUID- ORCID: 0000-0003-0807-1375
AD  - Department of Geriatric and Environmental Dermatology, Nagoya City University 
      Graduate School of Medical Sciences, Nagoya, Japan.
FAU - Ito, Takamichi
AU  - Ito T
AUID- ORCID: 0000-0002-2679-8546
AD  - Department of Dermatology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Matsushita, Shigeto
AU  - Matsushita S
AUID- ORCID: 0000-0003-2001-5341
AD  - Department of Dermato-Oncology/Dermatology, National Hospital Organization 
      Kagoshima Medical Center, Kagoshima, Japan.
FAU - Yoshino, Koji
AU  - Yoshino K
AD  - Department of Dermato-Oncology/Dermatology, Cancer Institute Hospital of Japanese 
      Foundation for Cancer Research, Tokyo, Japan.
AD  - Department of Dermato-Oncology/Dermatology, Tokyo Metropolitan Cancer and 
      Infectious Disease Center Komagome Hospital, Tokyo, Japan.
FAU - Fujisawa, Yasuhiro
AU  - Fujisawa Y
AD  - Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
AD  - Department of Dermatology, University of Ehime, Matsuyama, Japan.
FAU - Ishizuki, Shoichiro
AU  - Ishizuki S
AD  - Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
FAU - Segawa, Kojiro
AU  - Segawa K
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Yamamoto, Jun
AU  - Yamamoto J
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Hashimoto, Akira
AU  - Hashimoto A
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Kambayashi, Yumi
AU  - Kambayashi Y
AUID- ORCID: 0000-0003-3866-5609
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Asano, Yoshihide
AU  - Asano Y
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20230320
PL  - England
TA  - J Dermatol
JT  - The Journal of dermatology
JID - 7600545
RN  - LR24G6354G (eribulin)
RN  - P88XT4IS4D (Paclitaxel)
RN  - 7RN5DR86CK (pazopanib)
RN  - 1605-68-1 (taxane)
RN  - 0 (Taxoids)
SB  - IM
MH  - Female
MH  - Humans
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Drug Resistance, Neoplasm
MH  - East Asian People
MH  - *Hemangiosarcoma/drug therapy
MH  - Paclitaxel/therapeutic use
MH  - Retrospective Studies
MH  - *Skin Neoplasms/drug therapy
MH  - Taxoids/adverse effects/therapeutic use
OTO - NOTNLM
OT  - adverse events
OT  - cutaneous angiosarcoma
OT  - efficacy
OT  - second-line chemotherapy
EDAT- 2023/03/21 06:00
MHDA- 2023/07/03 06:41
CRDT- 2023/03/20 04:33
PHST- 2023/02/23 00:00 [revised]
PHST- 2022/12/20 00:00 [received]
PHST- 2023/03/06 00:00 [accepted]
PHST- 2023/07/03 06:41 [medline]
PHST- 2023/03/21 06:00 [pubmed]
PHST- 2023/03/20 04:33 [entrez]
AID - 10.1111/1346-8138.16786 [doi]
PST - ppublish
SO  - J Dermatol. 2023 Jul;50(7):912-916. doi: 10.1111/1346-8138.16786. Epub 2023 Mar 
      20.